Developer docs
API playgroundTry for free, no card

Search company profiles

Global Genomics Group

Full company profile

uuid000i9ln

Namestring
Global Genomics Group
Websiteurl
https://www.g3therapeutics.com/
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Global Genomics Group is a privately held, big-data driven life sciences company headquartered in Midlothian, United States. Founded in 2012, the firm operates with a headcount of 11-50 employees and is led by founder Szilard Voros, who serves as Chief Executive Officer. The company's primary web domain, g3therapeutics.com, signals an association with the G3 Therapeutics brand and a likely orientation toward therapeutic applications of genomic data analytics, though no specific product, pipeline, or platform details were disclosed in the available source material.

Specific product offerings, revenue mechanics, go-to-market strategy, customer segments, and technical architecture are not discernible from the aggregated source data. The corporate website currently renders only a CAPTCHA/verification interstitial with no substantive content, and no funding history, partnership disclosures, customer logos, pricing details, patents, certifications, management bios beyond the founder-CEO, or technology descriptions were captured. As such, the underlying analytical platform, therapeutic pipeline, regulatory posture, and commercial model cannot be characterized with confidence from the input evidence.

Short descriptiontext

Global Genomics Group is a privately held, big-data driven life sciences company founded in 2012 in Midlothian, United States. The firm employs 11-50 staff under founder-CEO Szilard Voros, operating under the G3 Therapeutics brand with a focus on therapeutic genomics.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMidlothian, United States
HQ citystring
Midlothian
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
genomics biomarker discovery, clinical genomics research, pharmacogenomics services, precision medicine analytics, life sciences data platforms
Industry5 codes
1Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
CodeHLAGANAIPrimaryYes
2Molecular Diagnostics & Genomics Laboratories
CodeHLAFAMAEPrimaryNo
3Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
CodeHLAAALADPrimaryNo
4Genomics & Next-Generation Sequencing (NGS) Services
CodeHLAGANAAPrimaryNo
5Genomics & Molecular Diagnostics (Trial Support)
CodeHLAGAEADPrimaryNo
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Genomics and Biomarker Discovery Services
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Global Genomics Group is a big-data driven life sciences company that applies genomics and large-scale data analytics to discover biomarkers and inform therapeutic development. Operating from Midlothian, Virginia under the G3 Therapeutics brand (g3therapeutics.com), the company supports translational research and clinical genomics programs for partner organizations. Its core activity is generating and interpreting genomic data to enable precision medicine and drug-discovery initiatives.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1G3 Therapeutics Big-Data Genomics Platform
CategoryGenomics and Biomarker Discovery Services
No data
Peers10 records
1Myriad Genetics
TypeBroad incumbent
Description

Myriad is a major genetic testing and precision medicine company with cardiovascular and multi-disease testing products. It represents the broad-incumbent commercialization model for molecular diagnostics that G3 could potentially partner with or compete against.

2Color Genomics
TypeEmerging player
Description

Color provides population-scale genetic testing and prevention programs, including cardiovascular risk panels, to employers, health systems, and pharma. It represents an emerging-platform peer with substantially greater commercial traction.

3Tempus AI
TypeBroad incumbent
Description

Tempus is a large precision medicine platform combining multi-omics, imaging, and clinical data with AI to support diagnostics and pharma research. It is a broad incumbent addressing the same big-data life sciences category G3 occupies, though at vastly larger scale.

4Human Longevity Inc.
TypeDirect peer
Description

HLI is a big-data driven genomics and preventive health company using whole-genome sequencing, imaging, and AI to predict disease risk. It is one of the closest direct comparables given the 'big-data driven life sciences' positioning and multi-omics analytical focus.

5Cleerly
TypeDirect peer
Description

Cleerly is a coronary CTA imaging-AI platform focused on cardiovascular risk assessment and disease characterization. It overlaps with G3's cardiovascular precision medicine positioning and shares the imaging-genomics analytical theme, though Cleerly is imaging-only and more commercially advanced.

6CardioDx
TypeDirect peer
Description

CardioDx developed Corus CAD, a blood-based gene expression test for obstructive coronary artery disease. It is a direct historical comparable in cardiovascular genomic diagnostics, though it has scaled differently and serves as a useful benchmark for category economics.

7Regeneron Genetics Center
TypeBroad incumbent
Description

Regeneron Genetics Center is one of the world's largest human genetics sequencing efforts, with significant cardiovascular disease focus. It is a broad incumbent in the same analytical category G3 addresses, though at pharma-scale.

8TenSixteen Bio
TypeEmerging player
Description

TenSixteen Bio is a discovery-stage company using somatic mosaicism and genomics to understand age-related disease risk including cardiovascular disease. It is an emerging-stage peer with overlapping analytical and disease-area focus.

9deCODE Genetics (Amgen)
TypeBroad incumbent
Description

deCODE is a population genomics pioneer now owned by Amgen, focused on genetic risk factors for disease including cardiovascular disease. It is the established incumbent in large-scale human genetics research with substantially greater scale and resources than G3.

10SomaLogic
TypeDirect peer
Description

SomaLogic operates a large-scale proteomics and multi-omics platform with applications in cardiovascular and metabolic disease. It shares G3's big-data, multi-omics biomarker discovery approach and serves pharma and clinical research customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Global Genomics Group

Genomics and Biomarker Discovery Servicesg3therapeutics.com

Global Genomics Group is a privately held, big-data driven life sciences company founded in 2012 in Midlothian, United States. The firm employs 11-50 staff under founder-CEO Szilard Voros, operating under the G3 Therapeutics brand with a focus on therapeutic genomics.

What Global Genomics Group does

Global Genomics Group is a privately held, big-data driven life sciences company headquartered in Midlothian, United States. Founded in 2012, the firm operates with a headcount of 11-50 employees and is led by founder Szilard Voros, who serves as Chief Executive Officer. The company's primary web domain, g3therapeutics.com, signals an association with the G3 Therapeutics brand and a likely orientation toward therapeutic applications of genomic data analytics, though no specific product, pipeline, or platform details were disclosed in the available source material.

Specific product offerings, revenue mechanics, go-to-market strategy, customer segments, and technical architecture are not discernible from the aggregated source data. The corporate website currently renders only a CAPTCHA/verification interstitial with no substantive content, and no funding history, partnership disclosures, customer logos, pricing details, patents, certifications, management bios beyond the founder-CEO, or technology descriptions were captured. As such, the underlying analytical platform, therapeutic pipeline, regulatory posture, and commercial model cannot be characterized with confidence from the input evidence.

Global Genomics Group firmographics

Firmographics
Name
Global Genomics Group
Website
https://www.g3therapeutics.com/
Company type
Private
Founded year
2012
Headcount range
11–50 employees
Short description
Global Genomics Group is a privately held, big-data driven life sciences company founded in 2012 in Midlothian, United States. The firm employs 11-50 staff under founder-CEO Szilard Voros, operating under the G3 Therapeutics brand with a focus on therapeutic genomics.
Ownership category
akta.pro rank

Global Genomics Group industry classification

Industry
Product category
Genomics and Biomarker Discovery Services
NAICS
Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro primary industry
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
akta.pro secondary industries
Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

  • Genomics biomarker discovery
  • Clinical genomics research
  • Pharmacogenomics services
  • Precision medicine analytics
  • Life sciences data platforms

Where Global Genomics Group is headquartered

Location

Headquarters

HQ city
Midlothian
HQ country
United States
HQ region
North America

Markets served

Global Genomics Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Global Genomics Group product offering

Product offering

Core offering

Global Genomics Group is a big-data driven life sciences company that applies genomics and large-scale data analytics to discover biomarkers and inform therapeutic development. Operating from Midlothian, Virginia under the G3 Therapeutics brand (g3therapeutics.com), the company supports translational research and clinical genomics programs for partner organizations. Its core activity is generating and interpreting genomic data to enable precision medicine and drug-discovery initiatives.

Differentiator

Problem solved

Functional benefit

Products and services

  • G3 Therapeutics Big-Data Genomics Platform

Companies that use Global Genomics Group

Customer profile

Ideal customer profiles1 record

Global Genomics Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Global Genomics Group competitors and assessment

Company assessment

Broad incumbents

  • Myriad Genetics: Myriad is a major genetic testing and precision medicine company with cardiovascular and multi-disease testing products. It represents the broad-incumbent commercialization model for molecular diagnostics that G3 could potentially partner with or compete against.
  • Tempus AI: Tempus is a large precision medicine platform combining multi-omics, imaging, and clinical data with AI to support diagnostics and pharma research. It is a broad incumbent addressing the same big-data life sciences category G3 occupies, though at vastly larger scale.
  • Regeneron Genetics Center: Regeneron Genetics Center is one of the world's largest human genetics sequencing efforts, with significant cardiovascular disease focus. It is a broad incumbent in the same analytical category G3 addresses, though at pharma-scale.
  • deCODE Genetics (Amgen): deCODE is a population genomics pioneer now owned by Amgen, focused on genetic risk factors for disease including cardiovascular disease. It is the established incumbent in large-scale human genetics research with substantially greater scale and resources than G3.

Emerging players

  • Color Genomics: Color provides population-scale genetic testing and prevention programs, including cardiovascular risk panels, to employers, health systems, and pharma. It represents an emerging-platform peer with substantially greater commercial traction.
  • TenSixteen Bio: TenSixteen Bio is a discovery-stage company using somatic mosaicism and genomics to understand age-related disease risk including cardiovascular disease. It is an emerging-stage peer with overlapping analytical and disease-area focus.

Direct peers

  • Human Longevity Inc. HLI is a big-data driven genomics and preventive health company using whole-genome sequencing, imaging, and AI to predict disease risk. It is one of the closest direct comparables given the 'big-data driven life sciences' positioning and multi-omics analytical focus.
  • Cleerly: Cleerly is a coronary CTA imaging-AI platform focused on cardiovascular risk assessment and disease characterization. It overlaps with G3's cardiovascular precision medicine positioning and shares the imaging-genomics analytical theme, though Cleerly is imaging-only and more commercially advanced.
  • CardioDx: CardioDx developed Corus CAD, a blood-based gene expression test for obstructive coronary artery disease. It is a direct historical comparable in cardiovascular genomic diagnostics, though it has scaled differently and serves as a useful benchmark for category economics.
  • SomaLogic: SomaLogic operates a large-scale proteomics and multi-omics platform with applications in cardiovascular and metabolic disease. It shares G3's big-data, multi-omics biomarker discovery approach and serves pharma and clinical research customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Global Genomics Group social profiles

Digital presence

Global Genomics Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Global Genomics Group leadership team

Management profile

Number of profiles

Profiles1 record

Global Genomics Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Global Genomics Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Genomics Group

What does Global Genomics Group do?

Global Genomics Group is a big-data driven life sciences company that applies genomics and large-scale data analytics to discover biomarkers and inform therapeutic development. Operating from Midlothian, Virginia under the G3 Therapeutics brand (g3therapeutics.com), the company supports translational research and clinical genomics programs for partner organizations. Its core activity is generating and interpreting genomic data to enable precision medicine and drug-discovery initiatives.

When was Global Genomics Group founded?

Global Genomics Group was founded in 2012. It employs 11 to 50 people.

Where is Global Genomics Group based?

Global Genomics Group is headquartered in Midlothian, United States, in the North America region.

Who are Global Genomics Group's main competitors?

Broad incumbents on record are Myriad Genetics, Tempus AI, Regeneron Genetics Center and deCODE Genetics (Amgen). Emerging players are Color Genomics and TenSixteen Bio. Direct peers are Human Longevity Inc., Cleerly, CardioDx and SomaLogic.

Does Global Genomics Group have an API?

No public API is recorded for Global Genomics Group.

What industry is Global Genomics Group in?

Global Genomics Group's product category is Genomics and Biomarker Discovery Services. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality WorldwideG3 Therapeutics and Aitia published research identifying triglyceride-rich LDL particles as a direct causal factor in atherosclerotic coronary artery disease (ASCAD), the leading cause of morbidity and mortality worldwide, using their Digital Twin models and Causal AI technology. The findings, validated genetically through the hepatic lipase gene, suggest that LDL-triglycerides could serve as a novel diagnostic biomarker and treatment target for cardiovascular disease. The companies describe this as a landmark result demonstrating how combining biological big data with causal AI can uncover disease drivers that have eluded researchers for decades.PR NewswireValo Announces Exclusive Partnership with G3 the World's Largest and Detailed Cardio-Metabolic DatasetsValo Health announced an exclusive drug discovery partnership with Global Genomics Group (G3), gaining access to what is described as the world's largest and most detailed cardio-metabolic dataset. Since forming the partnership, Valo has used its Opal Computational Platform to identify validated targets and approximately 20 early potential targets and disease subpopulations previously unresolved in the field. The collaboration aims to accelerate drug development by combining G3's patient data from its GLOBAL clinical study with Valo's machine learning algorithms to improve target identification and clinical trial precision.PR NewswireGlobal Genomics Group (G3) Presents Data for the First Time on the Exact Size of Lipoprotein (a) Particles that Cause Plaque Buildup in Coronary Arteries from its GLOBAL Clinical Study PlatformGlobal Genomics Group (G3) presented new research findings at the American Heart Association Annual Scientific Sessions in Chicago on November 12, 2018, revealing that smaller lipoprotein(a) particles with 24 kringle repeats or less are associated with coronary artery plaque buildup, while larger particles are not. The study utilized data from G3's prospective, international, multi-center GLOBAL clinical study combining cardiovascular CT imaging with precise Lp(a) particle measurements. The findings provide new insight into why some patients on LDL-lowering therapies like statins and PCSK9 inhibitors still experience cardiovascular events, potentially guiding the development of novel Lp(a)-lowering therapies.PR NewswireGlobal Genomics Group and Datavant Announce Strategic Partnership to Improve Design and Interpretation of Clinical TrialsGlobal Genomics Group (G3) and Datavant announced a strategic partnership on January 5, 2018, to improve the design and interpretation of clinical trials using data-driven approaches. The collaboration will combine G3's panomic dataset from approximately 8,000 patients with Datavant's Clinical Trial Data Cloud to develop new models for trial enrollment criteria, endpoints, and result contextualization. The companies aim to increase the odds of success and pace of drug development by leveraging artificial intelligence, machine learning, and biological Big Data analytics.PR NewswireGlobal Genomics Group (G3) In Collaboration with Semmelweis University in Budapest, Hungary, Unravel the Heritability of Adiposity, Paving the Way to New Drug Targets in Obesity and Non-Alcoholic FattGlobal Genomics Group and Semmelweis University announced findings from the BUDAPEST-GLOBAL study indicating that fat deposition in different body compartments is strongly influenced by genetic factors, with heritability rates ranging from 70% to 80%. The research, published in the International Journal of Obesity, identified common genetic drivers for fat accumulation across epicardial, subcutaneous, and visceral tissues. These insights are intended to help identify novel biological pathways and genetically validated drug targets for treating obesity and related metabolic diseases.PR NewswireGlobal Genomics Group Announces Breakthrough Diagnostic Blood Test for Plaque Detection in the HeartGlobal Genomics Group announced at the 2017 Biomarker Summit in San Diego that its diagnostic blood test "knowPLAQUETM" demonstrated strong performance in detecting atherosclerotic coronary artery disease from a standard blood draw. The mass-spectrometry-based metabolomics test, validated in approximately 1,096 subjects drawn from a 7,500-patient clinical study, can identify patients with coronary plaque and potentially reduce unnecessary nuclear stress tests and invasive angiograms. The company reported the test could save approximately 46% in costs associated with chest pain evaluation and is currently in discussions for implementation into clinical practice.PR NewswireGlobal Genomics Group (G3) Partners with Sanofi to Identify New Signaling Pathways in Atherosclerotic Cardiovascular DiseasesGlobal Genomics Group (G3) announced a research collaboration with Sanofi to identify new signaling pathways and targets involved in coronary artery disease. Under the agreement, the companies will use G3's G3LOBAL Database platform to study LDL-cholesterol regulation and determine which patients may benefit from novel pathway interventions. G3 will receive undisclosed payments from Sanofi for the collaboration.